Drug Profile
Ibritumomab tiuxetan - Acrotech Biopharma /Biogen
Alternative Names: 111In-ibritumomab tiuxetan; BAY86-5128; IDEC-129; IDEC-In2B8; IDEC-Y2B8; Indium-111 Ibritumomab tiuxetan; Monoclonal antibody IDEC-Y2B8; SH-L-749; Yttrium-90 ibritumomab tiuxetan; ZEVALIN; Zevalin; ZevamabLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Acrotech Biopharma; Bayer Yakuhin; Biogen; CASI Pharmaceuticals; Dana-Farber Cancer Institute; Schering Korea; Tufts-New England Medical Center
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-Hodgkin's lymphoma
- Discontinued Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma
Most Recent Events
- 16 Mar 2020 CASI Pharmaceuticals plans registration trial for Non-Hodgkin's lymphoma in China in early 2021
- 06 Mar 2019 Spectrum Pharmaceuticals completes sale of ibritumomab tiuxetan to Acrotech Biopharma
- 19 Feb 2019 The National Medical Products Administration (NMPA) of China approves a clinical trial application for the conduction of a confirmatory clinical trial of ibritumomab tiuxetan in Non-Hodgkin's lymphoma (Second-line therapy or greater)